Fibromyalgia Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in the Treatment of Primary Fibromyalgia
This is a 24-week, randomized, double-blind, placebo-controlled, trial to evaluate the safety, tolerability and efficacy of an orally administered growth hormone stimulating drug, (code named MK-0677) in the treatment of female subjects with primary fibromyalgia. The basis for this study is the observation that many fibromyalgia patients are growth hormone deficient; an earlier study of injectable growth hormone had shown benefit in this population of fibromyalgia patients.
This study examines whether MK-0677 treatment will improve symptoms of fibromyalgia (FM).
The rationale for this study is the observation that many fibromyalgia patients are growth
hormone deficient in terms of low levels of IGF-1, and that improving IGF-1 levels with
growth hormone injections has been shown to improve fibromyalgia symptoms.
MK-0677 is an orally administered growth hormone secretagogue manufactured by Merck & Co.,
Inc. that acts on the growth hormone secretagogue receptor in the anterior pituitary to
stimulate the release of growth hormone. This pathway represents an additional regulation of
growth hormone release from pituitary somatotrophs to that mediated by growth hormone
releasing hormone (stimulating) and somatostatin (inhibitory). Both stimulatory pathways
lead to a pulsatile release of growth hormone, with approximately 4 hour intervals between
peak levels. This growth hormone secretion leads to a rapid and robust up regulation of
IGF-1 levels by about 50 to 100% that can be maintained with chronic therapy at a dose of 25
mg/day.
The primary aims of this study are:
1. To evaluate the efficacy of MK-0677 25 mg in primary fibromyalgia subjects over a
24-week treatment period, as assessed by the FIQ.
2. To evaluate the safety and tolerability of MK-0677 25 mg in subjects with fibromyalgia.
The secondary aims of this study are to determine whether:
1. MK-0677 25 mg is superior to placebo in reducing muscle tenderness, as assessed by the
Fibromyalgia Myalgic Score (FMyS).
2. MK-0677 25 mg is superior to placebo in improving the subjects' global perception of
change in fibromyalgia symptoms, as assessed by the Subjects' Global Impression of
Change Questionnaire (PGIC).
3. MK-0677 25 mg is superior to placebo in improving the subjects' quality of life, as
assessed by the Quality of Life Questionnaire (QOL).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05659862 -
Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT03042728 -
Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program
|
N/A | |
Recruiting |
NCT06097091 -
Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia
|
N/A | |
Recruiting |
NCT04554784 -
Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia
|
N/A | |
Completed |
NCT03300635 -
Metabolism, Muscle Function and Psychological Factors in Fibromyalgia
|
N/A | |
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT03227952 -
Sensory Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT03166995 -
Postural Exercises in Women With Fibromyalgia
|
N/A | |
Recruiting |
NCT06237595 -
Vagus Nerve Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT01888640 -
Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
|
N/A | |
Completed |
NCT03641495 -
Pain Education and Therapeutic Exercise for Fibromyalgia
|
N/A | |
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Active, not recruiting |
NCT05128162 -
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
|
Phase 2 | |
Completed |
NCT04674878 -
Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia
|
N/A | |
Active, not recruiting |
NCT04084795 -
Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia
|
N/A | |
Completed |
NCT03129906 -
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
|
N/A | |
Completed |
NCT05058911 -
Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia
|
N/A | |
Recruiting |
NCT04571853 -
New Educational Tool for FM
|
N/A | |
Recruiting |
NCT04571528 -
Effectiveness of VIRTUAL FIBROWALK STUDY
|
N/A |